CN109846884A - 用tor激酶抑制剂治疗癌症 - Google Patents

用tor激酶抑制剂治疗癌症 Download PDF

Info

Publication number
CN109846884A
CN109846884A CN201910158858.3A CN201910158858A CN109846884A CN 109846884 A CN109846884 A CN 109846884A CN 201910158858 A CN201910158858 A CN 201910158858A CN 109846884 A CN109846884 A CN 109846884A
Authority
CN
China
Prior art keywords
base
pyrazine
substituted
unsubstituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910158858.3A
Other languages
English (en)
Chinese (zh)
Inventor
徐水蟾
克里斯汀·梅·海格
希瑟·雷蒙
辻俊哉
利萨·萨皮诺索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN109846884A publication Critical patent/CN109846884A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201910158858.3A 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症 Pending CN109846884A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261611428P 2012-03-15 2012-03-15
US61/611,428 2012-03-15
US201261715327P 2012-10-18 2012-10-18
US61/715,327 2012-10-18
CN201380024216.5A CN104271138A (zh) 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380024216.5A Division CN104271138A (zh) 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症

Publications (1)

Publication Number Publication Date
CN109846884A true CN109846884A (zh) 2019-06-07

Family

ID=48045717

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910158858.3A Pending CN109846884A (zh) 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症
CN201380024216.5A Pending CN104271138A (zh) 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380024216.5A Pending CN104271138A (zh) 2012-03-15 2013-03-14 用tor激酶抑制剂治疗癌症

Country Status (21)

Country Link
US (1) US20130245028A1 (enExample)
EP (1) EP2825171B1 (enExample)
JP (2) JP2015511964A (enExample)
KR (1) KR102057357B1 (enExample)
CN (2) CN109846884A (enExample)
AU (2) AU2013202992B2 (enExample)
BR (1) BR112014022700A2 (enExample)
CA (1) CA2867174C (enExample)
EA (1) EA028062B1 (enExample)
ES (1) ES2668279T3 (enExample)
IL (1) IL234639B (enExample)
MX (1) MX359227B (enExample)
MY (1) MY198666A (enExample)
NI (1) NI201400110A (enExample)
NZ (1) NZ628420A (enExample)
PH (1) PH12014502047B1 (enExample)
SG (1) SG11201405686PA (enExample)
TW (1) TWI622395B (enExample)
UA (1) UA114194C2 (enExample)
WO (1) WO2013138560A1 (enExample)
ZA (1) ZA201406708B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
MY189663A (en) * 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2908742C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
US20180369241A1 (en) * 2015-06-24 2018-12-27 Celgene Corporation Treatment of cancer with dnapk inhibitors
WO2017132235A1 (en) * 2016-01-26 2017-08-03 Dana-Farber Cancer Institute, Inc. METHODS FOR TREATING BRAIN METASTASES USING COMBINATIONS OF ANTI-P13K AND ANTI-mTOR AGENTS
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058572A1 (en) * 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂
CN102596910A (zh) * 2009-10-27 2012-07-18 奥赖恩公司 雄激素受体调节化合物
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
JP5279828B2 (ja) * 2008-07-10 2013-09-04 Ｊｘ日鉱日石金属株式会社 ハイブリッドシリコンウエハ及びその製造方法
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
WO2010044893A1 (en) * 2008-10-17 2010-04-22 Merck & Co. Combination therapy
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102245611A (zh) * 2008-10-27 2011-11-16 西格诺药品有限公司 用于与 mTOR/PI3K/AKT/途径相关的肿瘤适应症和疾病的 mTOR激酶抑制剂
WO2010058572A1 (en) * 2008-11-20 2010-05-27 Oncotherapy Science, Inc. Methods for diagnosing or treating prostate cancer
EP2430013B1 (en) * 2009-05-13 2014-10-15 Amgen Inc. Heteroaryl compounds as pikk inhibitors
CN102596910A (zh) * 2009-10-27 2012-07-18 奥赖恩公司 雄激素受体调节化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A SCHAYOWITZ等: ""Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR"", 《BRITISH JOURNAL OF CANCER》 *
江克华等: ""mTOR靶向治疗与前列腺癌关系的研究进展"", 《山东医药》 *

Also Published As

Publication number Publication date
US20130245028A1 (en) 2013-09-19
ES2668279T3 (es) 2018-05-17
AU2015213353A1 (en) 2015-09-03
KR102057357B1 (ko) 2019-12-18
EA028062B1 (ru) 2017-10-31
UA114194C2 (uk) 2017-05-10
JP2015511964A (ja) 2015-04-23
EP2825171B1 (en) 2018-03-14
CN104271138A (zh) 2015-01-07
SG11201405686PA (en) 2014-10-30
MX359227B (es) 2018-09-20
EP2825171A1 (en) 2015-01-21
TWI622395B (zh) 2018-05-01
MX2014011116A (es) 2015-04-08
CA2867174A1 (en) 2013-09-19
TW201343166A (zh) 2013-11-01
IL234639A0 (en) 2014-11-30
EA201491701A1 (ru) 2015-01-30
NZ628420A (en) 2016-04-29
PH12014502047A1 (en) 2014-12-10
KR20140138928A (ko) 2014-12-04
HK1202247A1 (en) 2015-09-25
JP6470822B2 (ja) 2019-02-13
CA2867174C (en) 2020-06-23
JP2018058861A (ja) 2018-04-12
MY198666A (en) 2023-09-14
AU2015213353B2 (en) 2017-07-27
AU2013202992B2 (en) 2015-09-03
PH12014502047B1 (en) 2014-12-10
WO2013138560A1 (en) 2013-09-19
ZA201406708B (en) 2016-05-25
BR112014022700A2 (pt) 2020-06-30
AU2013202992A1 (en) 2013-10-03
NI201400110A (es) 2015-01-12
IL234639B (en) 2020-05-31

Similar Documents

Publication Publication Date Title
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
CA2788678C (en) Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
CN104302295B (zh) 用tor 激酶抑制剂治疗癌症
KR102122617B1 (ko) Tor 키나제 억제자를 사용하는 암의 치료
TWI635862B (zh) 使用ｔｏｒ激酶抑制劑之癌症治療
AU2014254058A1 (en) Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
HK1239543A1 (en) Treatment of cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190607

WD01 Invention patent application deemed withdrawn after publication